Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size
Sainski, Amy M., Dai, Haiming , Natesampillai, Sekar, Pang, Yuan‐Ping , Bren, Gary D., Correia, Maria Cristina Miranda de Araujo, Sampath, Rahul , Rizza, Stacey A. , O’Brien, Daniel R. , Yao, Joseph D. , Badley, Andrew D. , Correia, Cristina , Cummins, Nathan W. , de Araujo Correia, Maria Cristina Miranda, Kaufmann, Scott H. , Correia, Maria Cristina Miranda de Araujo, Correia, Cristina , Badley, Andrew D , Pang, Yuan-Ping , Dai, Haiming

Journal of Virology | February 4, 2016 | Volume: 90 | Issue: 8 | Pages: 4032-4048

10.1128/jvi.03179-15 | PMID 26842479 Get It

ABSTRACT Understanding how some HIV-infected cells resist the cytotoxicity of HIV replication is crucial to enabling HIV cure efforts. HIV killing of CD4 T cells that replicate HIV can involve HIV protease-mediated cleavage of procaspase 8 to generate a fragment (Casp8p41) that directly binds and activates the mitochondrial proapoptotic protein BAK. Here, we demonstrate that Casp8p41 also binds with nanomolar affinity to the antiapoptotic protein Bcl-2, which sequesters Casp8p41 and prevents apoptosis. Further, we show that central memory CD4 T cells (T CM ) from HIV-infected individuals have heightened expression of BCL-2 relative to procaspase 8, possibly explaining the persistence of HIV-infected T CM despite generation of Casp8p41. Consistent with this hypothesis, the selective BCL-2 antagonist venetoclax induced minimal killing of uninfected CD4 T cells but markedly increased the death of CD4 T cells and diminished cell-associated HIV DNA when CD4 T cells from antiretroviral therapy (ART)-suppressed HIV patients were induced with αCD3/αCD28 to reactivate HIV ex vivo . Thus, priming CD4 T cells from ART suppressed HIV patients with a BCL-2 antagonist, followed by HIV reactivation, achieves reductions in cell-associated HIV DNA, whereas HIV reactivation alone does not. IMPORTANCE HIV infection is incurable due to a long-lived reservoir of HIV + memory CD4 T cells, and no clinically relevant interventions have been identified that reduce the number of these HIV DNA-containing cells. Since postintegration HIV replication can result in HIV protease generation of Casp8p41, which activates BAK, causing infected CD4 T cell death, we sought to determine whether this occurs in memory CD4 T cells. Here, we demonstrate that memory CD4 T cells can generate Casp8p41 and yet are intrinsically resistant to death induced by diverse stimuli, including Casp8p41. Furthermore, BCL-2 expression is relatively increased in these cells and directly binds and inhibits Casp8p41's proapoptotic effects. Antagonizing BCL-2 with venetoclax derepresses this antagonism, resulting in death, preferentially in HIV DNA containing cells, since only these cells generate Casp8p41. Thus, BCL-2 antagonism is a clinically relevant intervention with the potential to reduce HIV reservoir size in patients.
Snare‐Facilitated Retrieval of Entangled Impella Device
Eleid, Mackram F. , Melduni, Rowlens M. , Joyce, David L.

Journal of Interventional Cardiology | February 4, 2016 | Volume: 29 | Issue: 3 | Pages: 332-333

10.1111/joic.12275 | PMID 26842531 Get It

When a Surgical Colleague Makes an Error
Antiel, Ryan M. , Blinman, Thane A. , Rentea, Rebecca M. , Gonzalez, Katherine W. , Knott, E. Marty, Juang, David , Oyetunji, Tolulope A. , Holcomb, George, Lantos, John D. , Angelos, Peter

Pediatrics | February 4, 2016 | Volume: 137 | Issue: 3 | Pages: No page available

10.1542/peds.2015-3828 | PMID 26908678 Get It

Professionalism requires that doctors acknowledge their errors and figure out how to avoid making similar ones in the future. Over the last few decades, doctors have gotten better at acknowledging mistakes and apologizing to patients when a mistake happens. Such disclosure is especially complicated when one becomes aware of an error made by a colleague. We present a case in which consultant surgeons became aware that a colleague seemed to have made a serious error. Experts in surgery and bioethics comment on appropriate responses to this situation.
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
Ansell, Stephen M. , Villasboas, Jose Caetano, Villasboas, José C. , Witzig, Thomas E.

Oncotarget | February 3, 2016 | Volume: 7 | Issue: 11 | Pages: 13260-13264

10.18632/oncotarget.7177 | PMID 26848626 Get It

Clinical characteristics and outcomes in biclonal gammopathies
Mullikin, Trey C. , Dispenzieri, Angela , Lacy, Martha Q. , Lin, Yi , Dingli, David , Go, Ronald S. , Hayman, Suzanne R. , Zeldenrust, Steven R., Russell, Stephen J. , Lust, John A., Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Rajkumar, S. Vincent , Leung, Nelson , Gertz, Morie A. , Go, Ronald S , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

American Journal of Hematology | February 3, 2016 | Volume: 91 | Issue: 5 | Pages: 473-475

10.1002/ajh.24319 | PMID 26840395 Get It

A single monoclonal protein typically characterizes monoclonal gammopathies, but a small proportion may have more than one M protein identifiable. In the setting of symptomatic multiple myeloma (MM), the development of a new monoclonal protein following therapy is associated with better outcomes. As for the precursor conditions, monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM), there is limited information on the impact of a second monoclonal protein on the disease course, including progression and response to treatment. The outcomes of patients with MGUS and SMM with more than one monoclonal protein, after identifying 539 patients with biclonal proteins on electrophoresis and/or immunofixation, were reported. About 22 of 393 patients with MGUS/biclonal gammopathy of undetermined significance (BGUS) progressed to SMM (6), MM (11), AL (3), or WM (2), and 5 of 16 patients with biclonal SMM progressed to MM. The rate of progression for BGUS was approximately 1% per year, which is similar to MGUS with one monoclonal protein. The median estimated time of progression of biclonal SMM was 2.6 years; similar to monoclonal SMM. For patients with biclonal MM, both M spikes responded to treatment and, upon relapse, the original dominant M protein remained dominant as the disease progressed. In conclusion, the presence of a second monoclonal protein does not appear to affect the progression of precursor states and suggests multiple monoclonal proteins do not clinically impact one another in the course of the disease. Am. J. Hematol. 91:473–475, 2016. © 2016 Wiley Periodicals, Inc.
A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells
Turner, Elizabeth C., Huang, Chien‐Ling , Sawhney, Neha, Govindarajan, Kalaimathi, Clover, Anthony J. P., Martin, Kenneth, Browne, Tara C., Whelan, Derek , Kumar, Arun , Mackrill, John J. , Wang, Shaohua , Schmeckpeper, Jeffrey , Stocca, Alessia, Pierce, William Gamewell, Leblond, Anne‐Laure , Cai, Liquan , O’Sullivan, Donnchadh , Büneker, Chirlei Klein, Choi, Janet , MacSharry, John , Russell, Stephen J. , Caplice, Noel M. , Ikeda, Yasuhiro , Russell, Stephen J

Stem Cells | February 3, 2016 | Volume: 34 | Issue: 5 | Pages: 1354-1368

10.1002/stem.2319 | PMID 26840832 Get It

AbstractDisorders affecting smooth muscle structure/function may require technologies that can generate large scale, differentiated and contractile smooth muscle cells (SMC) suitable for cell therapy. To date no clonal precursor population that provides large numbers of differentiated SMC in culture has been identified in a rodent. Identification of such cells may also enhance insight into progenitor cell fate decisions and the relationship between smooth muscle precursors and disease states that implicate differentiated SMC. In this study, we used classic clonal expansion techniques to identify novel self-renewing Islet 1 (Isl-1) positive primitive progenitor cells (PPC) within rat bone marrow that exhibited canonical stem cell markers and preferential differentiation towards a smooth muscle-like fate. We subsequently used molecular tagging to select Isl-1 positive clonal populations from expanded and de novo marrow cell populations. We refer to these previously undescribed cells as the PPC given its stem cell marker profile, and robust self-renewal capacity. PPC could be directly converted into induced smooth muscle cells (iSMC) using single transcription factor (Kruppel-like factor 4) knockdown or transactivator (myocardin) overexpression in contrast to three control cells (HEK 293, endothelial cells and mesenchymal stem cells) where such induction was not possible. iSMC exhibited immuno- and cytoskeletal-phenotype, calcium signaling profile and contractile responses similar to bona fide SMC. Passaged iSMC could be expanded to a scale sufficient for large scale tissue replacement. PPC and reprogramed iSMC so derived may offer future opportunities to investigate molecular, structure/function and cell-based replacement therapy approaches to diverse cardiovascular, respiratory, gastrointestinal, and genitourinary diseases that have as their basis smooth muscle cell functional aberrancy or numerical loss.
Advanced Studies in Clinical and Experimental Research in Gastroenterology
Tachecí, Ilja , Varayil, Jithinraj Edakkanambeth , Zelinková, Zuzana , Kopáčová, Marcela , Zavoral, Miroslav , Edakkanambeth Varayil, Jithinraj, Edakkanambeth Varayil, Jithinraj

Gastroenterology Research and Practice | February 3, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-2

10.1155/2016/4253143 | PMID 26955389 Get It

Histopathological findings following pipeline embolization in a human cerebral aneurysm at the basilar tip
Kelly, Michael , Kadirvel, Ramanathan , Kallmes, David F. , Dai, Daying , Kallmes, David, Ding, Yonghong

Interventional Neuroradiology | February 3, 2016 | Volume: 22 | Issue: 2 | Pages: 153-157

10.1177/1591019915622165 | PMID 26842611 Get It

We report histopathological findings from a human cerebral aneurysm following treatment with a flow diverter. A 75-year-old male underwent flow diversion treatment (Pipeline Embolization Device (PED)) and coil embolization for treatment of an aneurysm at the basilar tip. At four months, angiography showed complete aneurysm occlusion; at 12 months angiography demonstrated that the aneurysm had reopened. The patient expired from brainstem compression. The aneurysm cavity was primarily filled with unorganized thrombus. Thick, interrupted neointima crossed the neck interface indicating blood flow into aneurysm through small channels. Along the parent artery the PED was covered by neointima having a measured thickness of 0.19 ± 0.01 mm; the maximal stenosis of the proximal parent artery was 27%. The perforating arteries that were crossed by the PED remained patent. Findings in this human case are similar to those in the elastase-induced aneurysms in rabbits.
Aging metabolism: Evitable or inevitable?
Lanza, Ian R. , Lanza, Ian R

Science Translational Medicine | February 3, 2016 | Volume: 8 | Issue: 324 | Pages: No page available

10.1126/scitranslmed.aaf2006 Get It

Lifestyle factors can explain many, but not all, of aging-related metabolic disturbances.
Evaluating the safety and the effects on colonic compliance of neostigmine during motility testing in patients with chronic constipation
Mouchli, Mohamad, Camilleri, Michael , Lee, T. , Parthasarathy, Gopanandan , Vijayvargiya, Prakhar , Halland, Magnus , Bharucha, Adil E. , Acosta, Andrés

Neurogastroenterology & Motility | February 3, 2016 | Volume: 28 | Issue: 6 | Pages: 871-878

10.1111/nmo.12786 | PMID 26840188 Get It

AbstractBackgroundNeostigmine, an acetyl cholinesterase inhibitor, stimulates colonic motor activity and may induce vagally mediated cardiovascular effects. Our aim was to evaluate effects of i.v. neostigmine on colonic compliance and its safety in patients with chronic constipation.MethodsWe retrospectively reviewed medical records of a selected group of 144 outpatients with chronic constipation who were refractory to treatment. These patients had undergone intracolonic motility and compliance measurements with an infinitely compliant balloon linked to a barostat. Data abstracted included barostat balloon mean volumes with increases in pressure (4 mmHg steps from 0 to 44 mmHg) before and after i.v. neostigmine. Vital signs and oxygen saturation before and after neostigmine were recorded.Key ResultsOf the 144 patients, 133 were female, mean age was 41.0 ± 15.4 years (SD), and duration of constipation was 12.9 ± 13.8 years. Among patients who had undergone colonic transit measurement by scintigraphy, the overall colonic transit at 24 h (geometric center, GC24 [n = 115]) was 1.5 ± 0.7 (normal >1.3), and at 48 h (GC48 [n = 75]) it was 2.3 ± 0.9 (normal >1.9). Neostigmine decreased colonic compliance at lower distension pressures (e.g., 12 and 20 mmHg [both p < 0.001]), but not at 40 mmHg. There were expected minor changes in vital signs in response to neostigmine in 144 patients; however, one patient developed unresponsiveness, significant bradycardia, hypotension, and muscular rigidity that responded to 400 mcg i.v. atropine.Conclusions & InferencesNeostigmine significantly decreases colonic compliance in patients with refractory chronic constipation. Symptomatic bradycardia in response to neostigmine should be promptly reversed with atropine.